Navigation Links
Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer
Date:2/5/2008

BRISBANE, Australia, Feb. 5 /PRNewswire/ -- Xenome Limited today announced the appointment of Ian Nisbet, PhD as the Company's Chief Executive Officer. Dr. Nisbet will also join Xenome's Board as Managing Director.

Dr. Nisbet has previously worked in senior management and executive roles in a number of biotechnology companies, including ChemGenex Pharmaceuticals Ltd, Meditech Research Ltd, Millennium Pharmaceuticals Inc, and CSL Ltd. He is a founder and partner in the biotechnology consultancy company Afandin Pty Ltd. He also serves on the board of the biotechnology companies Verva Pharmaceuticals Ltd, Ambri Ltd and Velacor Pty Ltd.

Xenome Chairman Ian Sandford stated, "We are delighted to have recruited Ian Nisbet to join Xenome. The Company has just executed a major discovery partnership with Amylin Pharmaceuticals and we will soon initiate a Xen2174 phase II study in post-operative pain. With the leadership of such an experienced biotechnology executive as Ian we look forward to the coming year with tremendous excitement and confidence."

"Ian's skills and experience make him the ideal person to lead Xenome in its next stage of development. Ian has worked in a variety of project management, business development, product development and executive management roles. During his time at Millennium he was project leader for the US approval and launch of VELCADE(R) and was part of the team that managed the merger of Millennium and COR Therapeutics in 2001. During his period as CEO of Meditech, Ian led the negotiations with Alchemia that resulted in the first merger of two publicly-traded Australian biotechnology companies."

Dr. Nisbet will assume the CEO position immediately and transition from his existing consultancy commitments over the next several months.

Further information:

Ian Nisbet, Chief Executive Officer

Xenome Ltd.

Tel: +61 431 709 121

E-mail: ian.
'/>"/>

SOURCE Xenome Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
2. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
3. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
4. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
5. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
6. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
7. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
8. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
9. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
10. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... December 11, 2009 -- Esco announces the opening of a NEW ... as a technical service, training and logistics center to support Esco,s ... New Product Introductions (NPI) for temperature-controlled laboratory equipment. , ... ... opening of a NEW 2nd North American facility in Marietta, OH. ...
(Date:12/10/2009)... -- Endologix, Inc. (Nasdaq: ELGX ), developer ... today that Dan Lemaitre, former President and CEO ... Directors effective December 11, 2009. Endologix now ... ,, Franklin D. Brown, Chairman of the Board, ... to the Endologix Board of Directors. He ...
(Date:12/10/2009)... -- Newly published research, by investigators, at ... (NESCI) in the journal STEM CELLS reported ... with "Limbal Stem Cell Deficiency" (LSCD) using ... need of suppressing their immunity. ,, ... a painful, blinding disease that requires long-term, ...
(Date:12/10/2009)... Biologic,Products, Inc. (Nasdaq: CBPO ) ("China Biologic," ... companies in China, today announced,that the Company,s senior ... the,NASDAQ MarketSite in New York City at 9:30 ... China Biologic,s common stock began ... 2009, under the ticker symbol "CBPO." , ...
Breaking Biology Technology:Endologix Appoints Dan Lemaitre to its Board of Directors 2Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4China Biologic Products to Ring NASDAQ Opening Bell 2China Biologic Products to Ring NASDAQ Opening Bell 3
... The nation's space agency announced this month it wants to return ... for the longer trip to Mars . Others say the ... Earth's lifeless satellite and head directly for the red planet, ... government should get out of the business of space flight and ...
... - Sonic Foundry, Inc. , has announced it ... shares of common stock at $3.75 per share. ... close on Dec. 27, 2006, will be used to ... the company's search technology and intellectual property protection. The ...
... national and international pipeline to Wisconsin might have been put ... a Norwegian biotechnology and stem cell research company, will be ... , ,CellCura, the fourth stem cell company to start or ... following an international search and will open in Madison with ...
Other Biology Technology:Flying to the moon? Take Wisconsin tech along 2Flying to the moon? Take Wisconsin tech along 3Flying to the moon? Take Wisconsin tech along 4CellCura could start an invasion of stem cell firms 2CellCura could start an invasion of stem cell firms 3
(Date:12/13/2009)... led by Yale University researchers has used nanosensors ... the first time. Their findings, which appear December ... Nature Nanotechnology , could dramatically simplify the way ... diseases. , The teamled by Mark ... Applied Science, and Tarek Fahmy, an associate professor ...
(Date:12/11/2009)... demand for premium fruit increases, growers are being ... And to boost their bottom line, orchard owners ... fruit quality while reducing labor costs. , Hand ... produce larger, healthier fruit, is among the most ... on fruit production overhead, and, ultimately, prices paid ...
(Date:12/11/2009)... identify and degrade the diverse types of defective proteins ... researchers Sabine C. Horn, Professor Thomas Sommer, Professor Udo ... Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have now ... enzyme complex that plays a critical role in the ... the identification and disposal of various defectively produced proteins. ...
Breaking Biology News(10 mins):Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Horizontal string trimmer reduces labor costs, increases peach size 2MDC researchers identify a scaffold regulating protein disposal 2Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference 12455 1Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference 12455 2IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 1IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 2Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis 47837 1Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis 47837 2Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis 47837 3
... Institute (NCI) and the National Human Genome Research ... of Health (NIH), today launched a comprehensive effort ... of cancer through the application of genome analysis ... called The Cancer Genome Atlas (TCGA), will begin ...
... the University of Pennsylvania School of Medicine have discovered ... RNA (pre-mRNA), a process once believed to only take ... this capability in dendrites, the investigators hope to relate ... cognitive dysfunction. Senior author James Eberwine, PhD, Professor of ...
... described as a mutation in mice that causes rapid ... humans from cancer. , Now, a team of ... has shown that the Quaking gene likely suppresses tumor ... GLI1, a cancer-causing oncogene highly associated with severe birth ...
Other Biology News:NIH launches comprehensive effort to explore cancer genomics 2NIH launches comprehensive effort to explore cancer genomics 3NIH launches comprehensive effort to explore cancer genomics 4RNA splicing occurs in nerve-cell dendrites 2RNA splicing occurs in nerve-cell dendrites 3Researchers discover new form of cancer gene regulation 2Researchers discover new form of cancer gene regulation 3
... DTNB , Ellman's reagent ... 69-78-3 *Storage: RT, When an enzyme-catalyzed ... not present in the substrate, it may be ... directly with the product to form a chromophore. ...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... is a protein based inhibitor of nonhuman ... most common and troublesome RNases including RNase ... can be used in any application where ... ideal for in vitro transcription and translation, ...
... RNaseOUT Recombinant Ribonuclease Inhibitor is ... pancreatic-type ribonucleases such as RNase ... RNaseOUT Recombinant Ribonuclease Inhibitor is ... molecular weight ~52 kDa. RNaseOUT ...
Biology Products: